#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Cytokine release syndrome Oropharyngeal cancer recurrent Liposarcoma Hereditary spastic paraplegia Bone marrow disorder NTRK gene fusion overexpression Myelodysplastic syndrome with excess blasts Acute on chronic liver failure Hypophosphatasia KBG syndrome Pleural mesothelioma malignant Hyperphagia Focal segmental glomerulosclerosis Lip and/or oral cavity cancer Alveolar proteinosis More trials…

    Learn about Rare Diseases

    Marginal zone lymphoma refractory – Basic Information Leiomyosarcoma recurrent – Treatment Myelodysplastic syndrome – Diagnostics CADASIL – Trials in Disease Vascular malformation – Life with Disease Haemophagocytic lymphohistiocytosis – Life with Disease Mitochondrial myopathy – Treatment Pemphigoid – Diagnostics Pulmonary sarcoidosis Pleural mesothelioma malignant – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Degarelix Masitinib COLESEVELAM HYDROCHLORIDE Imgn151 Nemvaleukin Alfa Hydroxypropylbetadex Ferrous Sulfate Exemestane Glofitamab NVG-2089 Vsf1.01 Benfotiamine Sacubitril SRSD107 FIBRIN Linaclotide Avb-101 VINBLASTINE Sodium Laurilsulfate Al8326 More therapies…

    Learn about Your Condition

    Cryoglobulinaemia Oesophagogastroscopy Exfoliation glaucoma Hyperchylomicronaemia Cerebral haemorrhage Urethral stenosis Malignant melanoma stage II Bone sarcoma Eosinophilic gastritis Cardiac failure acute Bronchostenosis Vulvovaginal dryness Vaginal cancer Bone marrow disorder Endocrine disorder More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Prostate cancer metastatic

  • Study of Niraparib, Abiraterone Acetate, and Prednisone for Patients with Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Abiraterone Acetate
    • Relugolix
    • Abiraterone
    Belgium Bulgaria Czechia Denmark France Germany +7

  • Study of Niraparib, Abiraterone Acetate, and Prednisone for Patients with Metastatic Prostate Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Abiraterone Acetate
    • Relugolix
    • Abiraterone
    Belgium Czechia France Germany Hungary Italy +4

  • Study of talazoparib and enzalutamide combination in men with DDR gene mutated metastatic castration-sensitive prostate cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Enzalutamide
    • Talazoparib
    Belgium Bulgaria Czechia Finland France Germany +6

  • Study on PF-07220060, Letrozole, and Fulvestrant for Patients with Advanced Breast Cancer, Prostate Cancer, and Other Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Pf-07220060 Monohydrate
    • Letrozole
    • Fulvestrant
    Czechia Slovakia

  • Study of enzalutamide alone versus enzalutamide with radium-223 combination in patients with bone metastatic castration-resistant prostate cancer with mild or no symptoms

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    Investigated Drugs:
    • Radium Ra 223 Dichloride
    • Enzalutamide
    Belgium Denmark France Ireland Italy Norway +2

  • Study of Pembrolizumab, Carboplatin, and Cabazitaxel for Patients with Aggressive Metastatic Castration-Resistant Prostate Cancer

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Cabazitaxel
    • Carboplatin
    • Pembrolizumab
    Spain
Previous Page
1 … 5 6 7 8
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!